Dublin, September 29, 2025 (Globe Newswire) – “Artificial Intelligence of Pharmaceutical Market Reports with Technology, Delivery, Applications, Deployment Modes, Country and Enterprise Analysis, 2025-2033” report has been added. ResearchAndMarkets.com Provided.
The pharmaceutical industry's artificial intelligence is expected to reach US$3.24 billion by 2024, increasing US$658.3 billion by 2033.
The pharmaceutical industry is to experience a combined annual growth rate (CAGR) of over 39.74% for the forecast period from 2025 to 2033. Mergers of AI technology could revolutionize drug discovery, improve patient outcomes and drive efficiency in operation in the pharmaceutical sector.
Pharmaceutical Artificial Intelligence (AI) is defined as the application of sophisticated computing technologies to improve drug development, discovery and patient care. By applying methodologies such as machine learning, natural language processing, and data analysis, AI supports predicting drug interactions, streamlining clinical trials, and tailored treatment regimens.
One important application of AI in this field is drug discovery to accelerate the identification of promising drug candidates by analyzing vast data sets and biological information, and significantly reduce the time and cost involved. AI also plays a key role in clinical trial management, identifying the right patient population, optimizing trial designs, and increasing the likelihood of success.
The use of AI in the pharmaceutical space is rapidly gaining popularity, putting pressure on healthcare innovation and increasing data availability. As pharma companies adopt this technology, they will enhance treatment outcomes, increase efficiency and ultimately revolutionize patient care.
Driven power to the growth of artificial intelligence in the pharmaceutical market
Discovery and development of faster drug discovery
AI is revolutionizing drug discovery discovery by reducing the time and spending involved in identifying future drug candidates. Machine learning algorithms can process large data sets, predict molecular interactions, improve accuracy and improve drug design. This speeds up preclinical research and allows for faster clinical trials. With increasing R&D spending and demand for timeline compression, AI-based platforms are ubiquitous.
Large pharmaceutical companies are working with AI companies to optimize their discovery pipeline. AI's speed, predictive power, and cost reduction are powerful stimulants for its use and essential tools for future pharma innovation. In January 2025, Roche Group member Genentech arrived at an inflection point that uses artificial intelligence (AI) and machine learning (ML) to transform the drug discovery process. “Loop Lab” is a device that introduces generated AI into drug R&D.
Advances in personalized medicine
The growing interest in personalized medicine is to promote the intake of Pharma AI. AI promotes the combination and interpretation of genetic, clinical, and lifestyle information to determine the appropriate personalized treatment. “Companion diagnosis.
In October 2024, BionTech and its artificial intelligence affiliate Instadeep revealed their AI plans at an event entitled “AI Day.” BionTech and companies will adopt fresh models and supercomputers to accelerate the creation of vaccines and cancer treatments. As Instadeep's in-house AI expert, BionTech is looking to expand the application of AI in the creation of customized vaccines and precision therapies. Particularly emphasized is the Deepchain platform, which utilizes a diverse range of OMICS data in drug design.
Increased collaboration and investment
Pharmaceutical companies, AI startups, and technology vendors are working together strategically to drive business growth and innovation. Pharmaceutical majors around the world are investing heavily in AI platforms to improve the efficiency of clinical trials, biomarker identification, and data processing. Venture capital and government support programs are also strengthening the development of AI-based solutions in life sciences.
For example, partnerships are directed at using AI to manage large quantities of genome sequencing and clinical research-generated data. This investment not only strengthens AI adoption, but also speeds up the commercialization of new drugs. A robust ecosystem of partnerships and funding is a key growth engine for the AI pharmaceutical market. In March 2022, Insilico Medicine partnered strategically with EQRX with the aim of integrating their respective expertise into the design and commercialization of De Novo Small molecules.
The challenges of artificial intelligence in the pharmaceutical market
Data Privacy and Regulatory Compliance
One of the key challenges in using AI at Pharmaceuticals is ensuring data privacy and compliance with high regulatory standards. Pharmaceutical research relies on health and genomic information for sensitive patients who need to meet regulations such as HIPAA and GDPR. Unauthorized access or misuse of data can lead to major legal and ethical issues.
Additionally, regulators still develop clear guidelines for AI use in drug development, creating uncertainty for stakeholders. Maintaining transparency, explainability and excellent AI practices is essential to overcome these challenges and gaining the trust of regulators, healthcare providers and patients.
High implementation costs and complexity
However, AI adoption in the pharmaceutical industry is slowing down due to high initial costs, infrastructure demand and technical complexity. Creating and integrating AI platforms involves large investments in computing capabilities, technical expertise and data management systems. Small and medium-sized pharmaceutical companies could be challenged to implement from a financial and technical perspective. Furthermore, because of legacy systems and non-standardized processes, AI can be difficult to integrate into established workflows.
These issues hamper large-scale adoption, especially in developing countries. Solving cost issues and ease of integration is important to maximize the possibilities of AI in pharmaceuticals.
Important attributes:
| Report attributes | detail |
| Number of pages | 200 |
| Forecast period | 2024-2033 |
| Estimated Market Value (USD) for 2024 | $3.24 billion |
| Forecast Market Value (USD) by 2033 | $65.83 billion |
| Combined annual growth rate | 39.7% |
| Covered areas | global |
Key Player Analysis: Overview, Key Person, Recent Developments, SWOT Analysis, Revenue Analysis
- Alphabet Inc. (Isomorphic Lab)
- Exscientia plc
- Reflexive drugs
- Insilico medicine
- Benevolentai
- Atomwise Inc.
- Xtalpi Inc.
- Deep Genomics
- Cloud Pharmaceuticals Inc.
- Cyclica Inc.
Market segmentation
technology
- Machine Learning
- Deep learning
- Natural Language Processing
- Computer Vision
- Generation AI
- Other AI techniques
Provided by
- Software Platform
- Services (AI-AAS, custom projects)
application
- Pre-clinical development of drug discovery
- Clinical trial design and patient recruitment
- Manufacturing and Quality Control
- Pharmacobvigilance and safety monitoring
- Sales, Marketing, Commercial Analysis
- Laboratory automation
- Other Applications
Deployment mode
- Cloud-based
- On-premises/Hybrid
country
North America
Europe
- France
- Germany
- Italy
- Spain
- England
- Belgium
- Netherlands
- turkey
Asia Pacific
- China
- Japan
- India
- South Korea
- Thailand
- Malaysia
- Indonesia
- Australia
- new zealand
latin america
Middle East and Africa
- Saudi Arabia
- uae
- South Africa
For more information about this report, please visit: https://www.researchandmarkets.com/r/1ktrg5
About ResearchAndmarkets.com
ResearchAndmarkets.com is the world's leading source of international market research reports and market data. Provides the latest data on international and regional markets, major industries, top companies, new products and latest trends.
-
Artificial intelligence in the pharmaceutical market
